Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3291219 | 0.86 | ALDH1A1 (0.66) | NPC1ALDH1A1SMN1; SMN2MAPK1CYP3A4 | |
| SCHEMBL7137680 | 0.86 | ALDH1A1 (0.66) | NPC1ALDH1A1SMN1; SMN2MAPK1CYP3A4 | |
| SCHEMBL8501497 | 0.84 | ALDH1A1 (0.63) | NPC1ALDH1A1SMN1; SMN2MAPK1CYP3A4 | |
| SCHEMBL8501501 | 0.84 | ALDH1A1 (0.63) | NPC1ALDH1A1SMN1; SMN2MAPK1CYP3A4 | |
| SCHEMBL1172383 | 0.83 | SMN1; SMN2 (0.78) | NPC1ALDH1A1SMN1; SMN2CYP3A4MAPT | |
| SCHEMBL18983905 | 0.83 | NPC1 (0.59) | NPC1ALDH1A1SMN1; SMN2CYP3A4MAPT | |
| SCHEMBL91307 | 0.83 | NPC1 (0.59) | NPC1ALDH1A1SMN1; SMN2CYP3A4MAPT | |
| SCHEMBL8415167 | 0.82 | SMN1; SMN2 (0.47) | NPC1ALDH1A1SMN1; SMN2MAPK1CYP3A4 | |
| SCHEMBL1997115 | 0.81 | NPC1 (0.70) | NPC1ALDH1A1SMN1; SMN2CYP3A4MAPT | |
| SCHEMBL27571763 | 0.81 | NPC1 (0.66) | NPC1ALDH1A1SMN1; SMN2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882707-B1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | ASAHI CHEMICAL IND (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-1013636-B1 | Preparation of allylic aromatic compounds | AMERSHAM HEALTH AS (NO) | 2003-07-09 | — | — | EP | disclosed |
| US-6545053-B1 | Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-04-08 | — | — | US | disclosed |
| US-6284894-B1 | AROMATIC AMINE IS REACTED FIRST WITH A NITRITE AND THEN WITH AN ALLYLIC OLEFIN HAVING AN ELIMINATABLE TERMINAL SUBSTITUENT. | NYCOMED IMAGING AS (NO) | 2001-09-04 | — | — | US | disclosed |
| US-6187809-B1 | BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| US-6172099-B1 | CARBAZOLE, DIBENZOFURAN, OR DIBENZOTHIOPHENE DERIVATIVES; DIETETICS, ANTIDIABETIC AGENTS; ANTILIPEMICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-1013636-A1 | Preparation of allylic aromatic compounds | NYCOMED IMAGING AS (NO) | 2000-06-28 | — | — | EP | disclosed |
| EP-0997458-A1 | NOVEL TRICYCLIC COMPOUNDS HAVING SATURATED RINGS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 2000-05-03 | — | — | EP | disclosed |
| US-6037362-A | CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ADRB3, MC2R, NR3C1 | NPC1 586/4885ALDH1A1 1815/4885SMN1; SMN2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.